This 2024 paper is a narrative review of cannabidiol, cannabis-derived products, regulation, pharmacology, and clinical use. It offers a useful overview of why purified CBD, commercial extracts, and broader cannabis products should not be treated as interchangeable. Its value is real, but it remains a narrative review, not a new trial, so its conclusions should be read as framing and synthesis rather than definitive proof.
Regulatory Digest 2026-03-07
✦ New Regulatory updates (digest-only, lower relevance) (57) [regulations.gov] Importer of Controlled-Bright Green(2024-20083)DEA1426 (57) [regulations.gov] Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429 (57) [regulations.gov] Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425 (57) [regulations.gov] Importer Controlled-VA Cooperative (2024-11795) DEA1374 (57)...
Cannabinoid Clinical Trials: GLP-1 Receptors and Mental Health
Clinical Takeaway GLP-1 receptor agonists showed measurable effects on risk for several common mental health conditions in this Mendelian randomization analysis, suggesting these medications may influence psychiatric outcomes beyond their metabolic effects....
Endocannabinoid System: Cannabis & Maternal Cytokines
Clinical Takeaway Cannabis use during pregnancy is linked to measurable suppression of key immune signaling proteins (cytokines) in the mother’s bloodstream. Because these cytokines play a critical role in supporting a healthy...
Endocannabinoid System & GLP-1 Receptor Mental Health Evidence
Clinical Takeaway GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were studied for their potential causal effects on ten common mental health conditions using genetic analysis data. The findings...
Endocannabinoid System & GLP-1 Mental Health Evidence
Clinical Takeaway GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were studied using genetic analysis to assess their causal effect on ten psychiatric conditions. The findings suggest these medications...
`Cannabinoids for Children: Clinical Evidence Reviewed`
Clinical Takeaway Current evidence on cannabinoids in pediatric patients spans 276 studies across multiple designs, capturing both plant-derived and pharmaceutical formulations used to treat medical conditions in children under 18. The research...